165 related articles for article (PubMed ID: 26721505)
1. Economic burden of toxicities associated with treating metastatic melanoma in eight countries.
Wehler E; Zhao Z; Pinar Bilir S; Munakata J; Barber B
Eur J Health Econ; 2017 Jan; 18(1):49-58. PubMed ID: 26721505
[TBL] [Abstract][Full Text] [Related]
2. Cost and economic burden of adverse events associated with metastatic melanoma treatments in five countries.
Vouk K; Benter U; Amonkar MM; Marocco A; Stapelkamp C; Pfersch S; Benjamin L
J Med Econ; 2016 Sep; 19(9):900-12. PubMed ID: 27123564
[TBL] [Abstract][Full Text] [Related]
3. Economic Burden of Toxicities Associated with Treating Metastatic Melanoma in the United States.
Bilir SP; Ma Q; Zhao Z; Wehler E; Munakata J; Barber B
Am Health Drug Benefits; 2016 Jun; 9(4):203-13. PubMed ID: 27688833
[TBL] [Abstract][Full Text] [Related]
4. Direct costs associated with adverse events of systemic therapies for advanced melanoma: Systematic literature review.
Copley-Merriman C; Stevinson K; Liu FX; Wang J; Mauskopf J; Zimovetz EA; Chmielowski B
Medicine (Baltimore); 2018 Aug; 97(31):e11736. PubMed ID: 30075584
[TBL] [Abstract][Full Text] [Related]
5. Review of the cost of diabetes complications in Australia, Canada, France, Germany, Italy and Spain.
Ray JA; Valentine WJ; Secnik K; Oglesby AK; Cordony A; Gordois A; Davey P; Palmer AJ
Curr Med Res Opin; 2005 Oct; 21(10):1617-29. PubMed ID: 16238902
[TBL] [Abstract][Full Text] [Related]
6. Comparison of treatment costs of grade 3/4 adverse events associated with erlotinib or pemetrexed maintenance therapy for patients with advanced non-small-cell lung cancer (NSCLC) in Germany, France, Italy, and Spain.
Banz K; Bischoff H; Brunner M; Chouaid C; de Castro Carpeño J; de Marinis F; Grossi F; Vergnenègre A; Walzer S
Lung Cancer; 2011 Dec; 74(3):529-34. PubMed ID: 21592611
[TBL] [Abstract][Full Text] [Related]
7. Health Care Resource Utilization and Associated Costs Among Metastatic Cutaneous Melanoma Patients Treated with Ipilimumab (INTUITION Study).
McArthur GA; Mohr P; Ascierto PA; Arance A; Banos Hernaez A; Kaskel P; Weichenthal M; Shinde R; Stevinson K
Oncologist; 2017 Aug; 22(8):951-962. PubMed ID: 28526721
[TBL] [Abstract][Full Text] [Related]
8. The economic burden of common adverse events associated with metastatic colorectal cancer treatment in the United States.
Latremouille-Viau D; Chang J; Guerin A; Shi S; Wang E; Yu J; Ngai C
J Med Econ; 2017 Jan; 20(1):54-62. PubMed ID: 27603498
[TBL] [Abstract][Full Text] [Related]
9. A cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancer.
Nuijten MJ; de Castro Carpeño J; Chouaid C; Vergnenègre A; Grossi F; Bischoff H; Heigener D; Walzer S
Lung Cancer; 2012 Jun; 76(3):465-71. PubMed ID: 22153602
[TBL] [Abstract][Full Text] [Related]
10. Cost of adverse events during treatment with everolimus plus exemestane or single-agent chemotherapy in patients with advanced breast cancer in Western Europe.
Campone M; Yang H; Faust E; Kageleiry A; Signorovitch JE; Zhang J; Gao H
J Med Econ; 2014 Dec; 17(12):837-45. PubMed ID: 25164472
[TBL] [Abstract][Full Text] [Related]
11. Economic burden of toxicities associated with metastatic colorectal cancer treatment regimens containing monoclonal antibodies.
Burudpakdee C; Zhao Z; Munakata J; Gao S; Trochlil K; Barber B
J Med Econ; 2012; 15(2):371-7. PubMed ID: 22181051
[TBL] [Abstract][Full Text] [Related]
12. Adverse event-related costs for systemic metastatic breast cancer treatment among female Medicaid beneficiaries.
Irwin DE; Masaquel A; Johnston S; Barnett B
J Med Econ; 2016 Nov; 19(11):1027-1033. PubMed ID: 27206801
[TBL] [Abstract][Full Text] [Related]
13. Estimating healthcare resource use associated with the treatment of metastatic melanoma in eight countries.
McKendrick J; Gijsen M; Quinn C; Barber B; Zhao Z
J Med Econ; 2016 Jun; 19(6):587-95. PubMed ID: 26823114
[TBL] [Abstract][Full Text] [Related]
14. Economic burden of selected adverse events in patients aged ≥65 years with metastatic renal cell carcinoma.
Hagiwara M; Hackshaw MD; Oster G
J Med Econ; 2013 Nov; 16(11):1300-6. PubMed ID: 24004437
[TBL] [Abstract][Full Text] [Related]
15. Economic burden of advanced melanoma in France, Germany and the UK: a retrospective observational study (Melanoma Burden-of-Illness Study).
Grange F; Mohr P; Harries M; Ehness R; Benjamin L; Siakpere O; Barth J; Stapelkamp C; Pfersch S; McLeod LD; Kaye JA; Wolowacz S; Kontoudis I
Melanoma Res; 2017 Dec; 27(6):607-618. PubMed ID: 28800027
[TBL] [Abstract][Full Text] [Related]
16. Economic burden associated with adverse events in patients with metastatic melanoma.
Arondekar B; Curkendall S; Monberg M; Mirakhur B; Oglesby AK; Lenhart GM; Meyer N
J Manag Care Spec Pharm; 2015 Feb; 21(2):158-64. PubMed ID: 25615005
[TBL] [Abstract][Full Text] [Related]
17. Costs associated with adverse events for systemic therapies in metastatic melanoma.
Fu AZ; Li Z; Tang J; Mahmood S; Whisman T; Qiu Y
J Comp Eff Res; 2018 Sep; 7(9):867-879. PubMed ID: 30192155
[TBL] [Abstract][Full Text] [Related]
18. Burden of corticosteroid use in patients with systemic lupus erythematosus: results from a Delphi panel.
Petri M; Bechtel B; Dennis G; Shah M; McLaughlin T; Kan H; Molta C
Lupus; 2014 Sep; 23(10):1006-13. PubMed ID: 24786783
[TBL] [Abstract][Full Text] [Related]
19. Global spending on orphan drugs in France, Germany, the UK, Italy and Spain during 2007.
Orofino J; Soto J; Casado MA; Oyagüez I
Appl Health Econ Health Policy; 2010; 8(5):301-15. PubMed ID: 20804223
[TBL] [Abstract][Full Text] [Related]
20. Self-monitoring of blood glucose (SMBG) in patients with type 2 diabetes on oral anti-diabetes drugs: cost-effectiveness in France, Germany, Italy, and Spain.
Tunis SL; Willis WD; Foos V
Curr Med Res Opin; 2010 Jan; 26(1):163-75. PubMed ID: 19919377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
